Background: Nowadays, the high prevalence of hypertension and its serious complications for affected patients have made this disease a major health issue worldwide. Hypertension, like other chronic diseases, reduces the patients’ quality of life. Maintaining and improving their lifestyles requires the serious support of families. Objectives: This study aimed to explore the effect of the family-centered empowerment model on the quality of life of patients with hypertension. Methods: This clinical trial was performed on 70 hypertensive patients who were referred to two comprehensive health centers in Zahedan University of Medical Sciences in Zahedan, southeastern Iran, in 2020. The participants were selected and randomly allocated based on the inclusion criteria to the intervention (n = 35) and control (n = 35) groups using the consort. The participants in the intervention group received training in four 60-min sessions individually based on the family empowerment model. To collect data, a personal information form and the Quality of Life Questionnaire for hypertensive patients were used. The questionnaire was completed before the intervention and one and three months after the intervention by a self-report method. The collected data were analyzed by SPSS-22 using the independent samples t test, chi-square test, and repeated-measures analysis of variance. Results: The results of repeated-measures analysis of variance regarding the effect of time and group on the quality of life showed a statistically significant difference in the second and third phases between the two groups. In other words, the two variables of intervention and time affected the mean score of quality of life, and a statistically significant difference was observed in the measured time intervals (P < 0.001). Conclusions: This study showed that implementing the family-centered empowerment model improves the quality of life of patients with hypertension. Therefore, we recommend employing this method by nurses to engage the patients with chronic diseases and their families in the process of treatment.
Introduction: In previous studies, kidney stones was reported as a common complication in general populations. Objectives: This study aimed to evaluate kidney stone incidence and related factors in hemodialysis patients. Patients and Methods: This descriptive-analytical study was conducted on 284 hemodialysis patients in the Zahedan. Demographic and clinical data were collected. The incidence rate of kidney stone was calculated. The correlation between kidney stone incidence with predicting factors was explored by multivariate logistic regression. Results: Results demonstrated that most patients were male, with a mean age of 48.81 ± 16.84 years. The correlation between kidney stone incidence with gender, race, smoking, and blood group was not significant (P > 0.05); however, its correlation with diabetes mellitus, urinary tract infection, age, and body mass index (BMI) was significant (P < 0.05). The kidney stone incidence rate was 23.24%, while diabetes mellitus, urinary tract infection, older age, and higher BMI were the most common predictors. Conclusion: Diabetes mellitus, urinary tract infection, older age, and higher BMI were the common predictors for kidney stone incidence in hemodialysis patients. Identifying kidney stone incidence predictors in patients with hemodialysis can be helping in lower complications.
Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant appeared in South Africa for the first time. The high prevalence of its mortality in elderly patients has caused an increase in anxiety triggered by this disease in aged people. Objectives: The aim of this study is to evaluate the anxiety related-COVID-19 in the SARS-CoV-2 Omicron variant and its related factors in elderly patients who are candidates for cataract surgery. Patients and Methods: This descriptive-analytical study was conducted on 159 over 65 years old patients who are candidates for cataract surgery. Easy and accessible sampling methods were employed to select samples. Demographic characteristics sheet and the Corona Disease Anxiety Scale (CDAS) questionnaire were filled out by them. Fisher’s exact test, Mann-Whitney U and binary logistic regression tests were conducted for data analysis. Results: The results showed that out of 159 patients, 57.9% were female, with a mean age of 73.09 ± 9.64 years. The anxiety level of 70.4% of patients was mild or non-anxiety and 29.6% was moderate or severe. The correlation between anxiety related to COVID-19 with age, gender, vaccination status and history of being infected by COVID-19 was significant (P<0.05); however, the correlation with the job, place of residence and marital status were not significant (P>0.05). Conclusion: We concluded that older age, female gender, non-vaccinated and having no history of being infected by COVID-19 are the most influential factors that increase anxiety triggered by COVID-19 in elderly patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.